Thromboprophylaxis in patients with moderate COVID-19
Not Applicable
Recruiting
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000046519
- Lead Sponsor
- Port said University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 124
Inclusion Criteria
Not provided
Exclusion Criteria
History of impairment of hemostasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (IMCU) duration, patients transferred to in (ICU),
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of anticoagulants in thromboprophylaxis for moderate COVID-19 are explored in JPRN-UMIN000046519?
How does thromboprophylaxis in JPRN-UMIN000046519 compare to standard-of-care anticoagulants for moderate COVID-19 outcomes?
Which biomarkers predict response to thromboprophylaxis in moderate COVID-19 patients from JPRN-UMIN000046519?
What adverse events, particularly bleeding complications, are associated with thromboprophylaxis in JPRN-UMIN000046519's moderate COVID-19 study?
Are combination therapies of thromboprophylaxis with dexamethasone or remdesivir effective in moderate COVID-19 (JPRN-UMIN000046519)?